Option chain shows key data for Rivulet Entertainment's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Rivulet Entertainment.

Rivulet Entertainment (OTC:RIVF) Stock, Option Chain

Rivulet Entertainment Inc, formerly Advanced Voice Recognition Systems Inc is a software development company that is engaged in creating interface and application solutions for speech recognition technologies. It holds six issued patents and is also involved in patent monetization.

RIVULET ENTERTAINMENT INC by Rivulet Entertainment, Inc.

Rivulet Entertainment Inc

Northland Capital Markets analyst Gus Richard maintains CEVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NASDAQ">CEVA</a>) with a Outperform and raises the price target from $31 to $35.

News

Price Target

Analyst Ratings

CEVA

Northland Capital Markets Maintains Outperform on CEVA, Raises Price Target to $35

At the beginning of 2024, Benzinga noted <a target="_blank" href="https://www.benzinga.com/markets/commodities/24/01/36452207/4-mining-stocks-to-watch-in-2024-aura-oceanagold-alphamin-b2gold" rel="noreferrer noopener">four mining stocks</a> to follow while evaluating tailwinds like green tech demand and persistent inflation. Although gold, as a benchmark, has had one of the best years on record, outperforming even the surging equities market, miners delivered mixed results.
<h3 class="wp-block-heading">Aura Minerals</h3>
Aura Minerals (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/ORAAF#OTCQX">ORAAF</a>) is a gold and copper miner focused on Central and South America, with primary operations in Brazil, Mexico, and Honduras. During 2024, the company made notable asset acquisitions, obtaining rights to explore Pé Quente and Pezão projects to boost its reserves. The company also acquired Bluestone Resources, a junior miner with a promising high-grade gold deposit in Guatemala.
The company recently reported its second-best quarter by adjusted EBITDA and decreased all-in-sustained costs to $1,292/ounce. The stock was a strong performer, rising 85% year-to-date.
<h3 class="wp-block-heading">OceanaGold</h3>
OceanaGold (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OCANF#OTC">OCANF</a>) is a mid-tier gold and copper producer with production in New Zealand, the Philippines, and the United States. It originally started as Macraes Mining Company, named after the foundation asset in New Zealand, which produced over 5 million ounces of gold since 1990. During 2024, the company focused on advancing the Didipio gold and copper project in the Philippines and providing initial mineral reserves for the proposed Wharekirauponga gold mine in New Zealand of 1.2 million ounces, with a projected IRR of 24% at a gold price of $2,400 per ounce.
Per the latest earnings, the company increased quarterly production from all sites, achieving a net profit of $61 million and boosting cash reserves. Since the beginning of the year, the stock rose 60.4%.
<h3 class="wp-block-heading">Alphamin Resources</h3>
Alphamin Resources (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AFMJF#OTC">AFMJF</a>) is a miner focused on producing tin, a critical mineral used for metal coating and the production of superconducting magnets. The company's principal project is the Bisie mine, the world's highest-grade tin mine.
In 2024, Alphamin achieved record quarterly tin production, in excess of 4,000 tons, staying on track to its production target of 20,000 tons annually. For the next growth step, the firm plans to connect its mining sites to have one producing unit feeding two processing facilities. Management estimates they could scale up output to 25,000 tons. The last drill campaign added 175,000 tons of reserves. Alphamin's stock returned 21.1% year-to-date.
<h3 class="wp-block-heading">B2Gold</h3>
B2Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTG#AMEX">BTG</a>) is a mid-tier mining company operating mines in emerging markets and exploration activities in more stable jurisdictions like Canada and Finland. The company's principal asset is the Fekola mine in Mali, with an annual production exceeding 500,000 ounces. Its other operating assets include Masabe in the Philippines and Otjikoto in Namibia.B2Gold had a volatile year, as <a target="_blank" href="https://www.benzinga.com/news/guidance/24/12/42516175/barrick-warns-about-destabilization-in-mali-could-halt-one-of-its-largest-mines" rel="noreferrer noopener">escalating instability in Mali</a> resulted in the off-site deaths of multiple employees and an increasingly complex situation with the ruling military junta. Furthermore, the higher-than-anticipated capital costs for a project in northern Canada have weighed on financials. Owing to these setbacks, B2Gold has lost 14.4% year-to-date.
As of December 20, VanEck Junior Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDXJ#NYSE">GDXJ</a>) returned 16.67% year-to-date.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42628973/billionaire-investor-bullish-on-gold-miners-including-this-penny-stock" target="_blank" rel="noreferrer noopener">Billionaire John Paulson Bullish On Gold Miners, Including This Penny Stock</a></li>
</ul>
Image via Shutterstock

Commodities

Trading Ideas

AFMJF

GDXJ

OCANF

ORAAF

Reviewing Benzinga's Mining Watchlist For 2024

COSCIENS Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCI#NASDAQ">CSCI</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CSCI#TSX">CSCI</a>) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today provided a corporate update and reiterated its pipeline prioritization.
"Over the course of the last several months following the merger, we have taken strategic and deliberate steps to evaluate and prioritize our combined pipeline of products and programs. Through this effort, we have thoroughly evaluated the potential of our assets and prioritized the areas that we believe are high-value opportunities, and we plan to move forward focusing our resources on advancing a pipeline of natural-based products leveraging our core technologies. We believe that this focus, spanning cosmeceuticals, nutraceuticals and pharmaceuticals, positions us with near and long-term life science growth drivers and the potential to become a global leader in natural-based products for health and wellness," stated <a href="https://www.globenewswire.com/Tracker?data=XGEB5e3QJGs0rAZIEn9x3enzUNiQFyPKt0kKPnr1xjTKfNlMsAdacP2YgVUlHhRD5gSQwGVhUPozg71YRlEgMHW38CEK1DDrHxEAYh0ecfkZ-ZDfyBuCxSyjQEpSMY-zoQ4WmYnYksKrGXJWHDk_2w==">Gilles Gagnon, M.Sc., MBA, President and CEO</a> of COSCIENS. "In addition, we have continued to make progress driving revenues and growing our active ingredients base business. We are looking to kick off 2025 with a clear line of sight towards execution of our business plan and believe we are well-positioned for a transformational year."
Development Projects Update
Pharmaceuticals:
<ul>
<li>Avenanthramides Tablets (Avs) in Development as an Anti-Inflammatory: The Phase 1-2a clinical trial being conducted at the Montreal Heart Institute has fully completed the Phase 1 part of the study with 72 subjects tested. No significant side effects have been observed from ascending doses ranging from 30 mg to 960 mg. The Company expects the Phase 2a efficacy study will be initiated in Q1 2025, with expected completion in Q3 2025. &nbsp;</li>
</ul>
Cosmeceuticals:
<ul>
<li>Enriched Oat Flour with High Concentration of Avenanthramides: We have successfully produced and sold small batches for inclusion in cream formulations. &nbsp;</li>
<li>JuventeDC Product Line: New website, <a href="https://juventedc.com/en">juventedc.com</a>, was launched on December 19, 2024. &nbsp;</li>
</ul>
Nutraceuticals:
<ul>
<li>Yeast Beta Glucan (YBG) Powder - Immune Booster: Our YBG product has been successfully manufactured as part of our PGX scale up project in Edmonton, Alberta. Our YBG product is being finalized in capsule form with the goal to commercialize it as an immune booster in Q2 2025. &nbsp;</li>
<li>Oat Beta Glucan (OBG) Chewable Bar – Cholesterol Reduction: We have successfully developed a unique, standardized formulation for a healthy confection which includes a high concentration of OBG with daily dosage according to approved claims in 10 developed countries. The substantive claims include reduction of LDL cholesterol, supporting cardiovascular health reduction of Type 2 diabetes risks, source of fiber for the maintenance of general good health and support of a healthy digestive system. COSCIENS' team anticipates the official commercial launch of its chewable bar OBG natural health product in Q1 2025, marking an important chapter in the Company's journey toward promoting wellness while expanding its business model. &nbsp;</li>
</ul>
Macimorelin:
<ul>
<li>On August 27, 2024, the Company announced that the Phase 3 safety and efficacy study AEZS-130-P02 (the "DETECT-trial") evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency ("CGHD") had failed to meet its primary endpoints according to the definitions in the study protocol. Based on the results of the study, we are prioritizing our pipeline moving forward and repositioning the Company as a pure play Life Science's business offering natural-based products. Therefore, while maintaining the current commercial indication for the use of macimorelin for the diagnosis of Adult Growth Hormone Deficiency ("AGHD"), the Company has decided to not make any future investments in macimorelin for the diagnosis of CGHD. Consequently, in order to further ensure the streamlining of operations and reduce costs, the roles of some additional members of management have been terminated, including Dr. Nicola Ammer, Chief Medical Officer, which will be ending on March 31, 2025. &nbsp;</li>
</ul>

CSCI

TSX:CSCI

COSCIENS Biopharma Shifts Focus to Natural-Based Products for Health & Wellness

Barclays analyst David Strauss maintains Textron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) with a Overweight and lowers the price target from $104 to $95.

Barclays Maintains Overweight on Textron, Lowers Price Target to $95

Ennis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBF#NYSE">EBF</a>) just disclosed its Q3 earnings on Monday, December 23, 2024 at 06:00 AM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Ennis missed estimated earnings by 0.0%, reporting an EPS of $0.39 versus an estimate of $0.39.
Revenue was down $4.85 million from the same period last year.
<h3>Historical Earnings Summary</h3>
The company missed on EPS by $0.02 in the last quarter, resulting in a 2.0% increase share price change the following day.
Here's a look at Ennis's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.42</td>
<td>0.36</td>
<td>0.39</td>
<td>0.42</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.40</td>
<td>0.41</td>
<td>0.39</td>
<td>0.38</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>104.58M</td>
<td>100.85M</td>
<td>101.40M</td>
<td>102.40M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>99.04M</td>
<td>103.11M</td>
<td>97.43M</td>
<td>104.62M</td>
</tr>
</tbody>
</table>

 Listen to the earnings announcement yourself by <a href="">clicking here</a>. 
To track all earnings releases for Ennis <a href="https://www.benzinga.com/quote/EBF/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Ennis: Q3 Earnings Insights

Stifel analyst Benjamin Nolan maintains New Fortress Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) with a Buy and raises the price target from $16 to $17.

Stifel Maintains Buy on New Fortress Energy, Raises Price Target to $17

Chinese company Sophgo whose Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>)-made chip was allegedly found in a Huawei Technologies Co artificial-intelligence processor, faces potential blacklisting from the U.S.
Bitcoin mining equipment supplier Bitmain affiliate Sophgo is the latest Chinese company potentially on the U.S. semiconductor embargo list, citing national security threats, Reuters reports.
In October, tech research firm TechInsights reportedly discovered the Taiwan Semiconductor chip in the Huawei 910B and told the chipmaker, which notified the U.S. Commerce Department.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/12/42621868/nvidia-secures-eu-approval-for-runai-deal-us-probes-china-export-breach" rel="noreferrer noopener">Nvidia Secures EU Approval For Run:ai Deal, US Probes China Export Breach</a>
After determining the chip matched Sophgo&#8217;s design, Taiwan Semiconductor suspended <a target="_blank" href="https://www.benzinga.com/government/24/10/41573440/whats-going-on-with-taiwan-semiconductor-stock-on-monday" rel="noreferrer noopener">shipments to the company</a>.
Sophgo, a supplier to local governments and state-owned firms like China Telecom, denied the charges in October. Huawei also denied the allegations, Reuters report said.
On November 11, the U.S. urged Taiwan Semiconductor to suspend shipments of seven-nanometer or more advanced chips to China. The U.S. sanctions forbid exporters from shipping goods and technology without a license, which will likely be denied.
In December, the <a target="_blank" href="https://www.benzinga.com/government/regulations/24/12/42265847/biden-targets-china-with-new-chip-restrictions-nvidia-slides." rel="noreferrer noopener">U.S. government sanctioned</a> 140 Chinese semiconductor firms, including chip equipment manufacturers such as&nbsp;Naura Technology Group and others, targeting advanced memory chips and chipmaking tools.
The U.S. added telecom equipment maker Huawei to its Entity List in 2019, restricting its access to foreign-made chips since 2020. However, over the past two years, Chinese state-run universities building AI tools and police stations splurged on Sophgo and Bitmain AI chips to upgrade their capabilities.
The U.S. sanctions prompted Huawei to diversify into an AI chip powerhouse. China considers Huawei&#8217;s Ascend 910B the most advanced AI chip in the country. Huawei plans to commercialize its Ascend 910C in early 2025 to rival Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Taiwan Semiconductor stock is trading upwards on Monday. At the end of last week, the Taiwanese contract chipmaker&#8217;s stocks were trading at ~ a 25% premium to those in its domestic market, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-12-23/us-investors-pay-biggest-premium-for-tsmc-shares-in-two-months?srnd=phx-technology&amp;sref=TBDibEcD" rel="noreferrer noopener">reports</a>, signaling investors&#8217; conviction in the AI frenzy.
This marks a record premium since October 17, beating the quarter&#8217;s daily average of 19%.
Price Action: TSM stock is up 1.75% at $200.67 premarket at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42614272/us-listed-chinese-stocks-react-as-central-bank-keeps-key-rates-steady-amid-yuan-challenges-and-fed-cuts" target="_blank" rel="noreferrer noopener">US-Listed Chinese Stocks Fall As China&#8217;s Central Bank Keeps Key Rates Steady</a></li>
</ul>
Photo via Shutterstock

Government

Regulations

Emerging Markets

Tech

Media

NVDA

Biden Administration Targets Chinese Firm Over Taiwan Semiconductor Chip Found in Huawei Tech

Barclays analyst Balaji Prasad maintains Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) with a Equal-Weight and lowers the price target from $7 to $3.

RVNC

Barclays Maintains Equal-Weight on Revance Therapeutics, Lowers Price Target to $3

Stifel analyst Stephen Gengaro maintains Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) with a Buy and lowers the price target from $60 to $59.

Stifel Maintains Buy on Schlumberger, Lowers Price Target to $59

Barclays analyst Ramsey El-Assal maintains Paychex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) with a Equal-Weight and raises the price target from $135 to $140.

PAYX

Barclays Maintains Equal-Weight on Paychex, Raises Price Target to $140

Shares of Rumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) rose sharply in today's pre-market trading after the company announced it has entered into a definitive agreement for a strategic <a href="https://www.benzinga.com/24/12/42634166/rumble-stock-soars-on-775-million-investment-from-tether-what-to-know">investment of $775 million from Tether</a>.
Tether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>) has agreed to purchase 103.33 million shares of Rumble Class A Common Stock at a price per share of $7.50, totaling $775 million in gross proceeds to Rumble.
Rumble shares jumped 43.3% to $10.31 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Reliance Global Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) gained 234% to $4.01 in pre-market trading.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) gained 88.6% to $3.32 in pre-market trading. Phio Pharmaceuticals, last week, announced a $1.15 million registered direct offering priced at-the-market under Nasdaq rules.</li>
<li>Edible Garden AG Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) climbed 82.3% to $0.4334 in pre-market trading after surging 63% on Friday. Edible Garden recently announced it experienced a 51% year-over-year increase in its preliminary Thanksgiving period sales.</li>
<li>JIADE Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) gained 60.9% to $0.8530 in pre-market trading. JIADE received Nasdaq notification letter regarding minimum bid price deficiency.</li>
<li>American Battery Technology Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABAT#NASDAQ">ABAT</a>) rose 44.1% to $1.60 in pre-market trading. On Friday, American Battery Technology priced its $5 million registered direct offering of 5 million shares at $1.00 per share.</li>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) gained 30.9% to $3.60 in pre-market trading after jumping more than 36% on Friday.</li>
<li>Brenmiller Energy Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>) rose 28.8% to $0.9700 in pre-market trading after the company was awarded ISO/IEC 27001:2022 certification.</li>
<li>Honda Motor Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) gained 18% to $28.19 in pre-market trading. Honda Motor and Nissan Motor Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSANY#OTC">NSANY</a>) have started talks for a potential merger.</li>
<li>Kodiak Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) rose 14.9% to $9.94 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares tumbled 28.9% to $0.0531 in pre-market trading after jumping 14% on Friday. Conduit Pharmaceuticals recently announced it entered an agreement with Sarborg to leverage AI and its cybernetics platform to evaluate key deliverables across multiple areas of operations.</li>
<li>Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) declined 25.7% to $0.6759 in pre-market trading after jumping around 101% on Friday.</li>
<li>Onfolio Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONFO#NASDAQ">ONFO</a>) fell 24.4% to $1.21 in pre-market trading. Onfolio Holdings announced a quarterly preferred stock cash dividend of 75 cents per share.</li>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) shares fell 24.3% to $0.6703 in pre-market trading after declining 9% on Friday.</li>
<li>ConnectM Technology Solutions Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTM#NASDAQ">CNTM</a>) shares dipped 20% to $0.83 in pre-market trading after falling 8% on Friday. ConnectM Technology Solutions, last week, announced a year-over-year increase in third-quarter revenue results.</li>
<li>TPI Composites, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) fell 19.2% to $1.94 in today's pre-market trading after jumping 97% on Friday.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) dipped 17.8% to $0.2293 in pre-market trading after jumping 64% on Friday. Aptose Biosciences, last week, announced it was granted an extension to provide compliance evidence for a continued Nasdaq listing.</li>
<li>Core Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLB#NYSE">CLB</a>) fell 11% to $15.00 in pre-market trading.</li>
<li>Astria Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) shares fell 10.8% to $8.53 in pre-market trading.</li>
<li>SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) fell 8.5% to $5.41 in pre-market trading.</li>
</ul>
Now Read This: &lt;a href=&#8221;https://www.benzinga.com/news/earnings/24/04/38307448/investor-sentiment-decreases-further-s-p-500-falls-for-fourth-straight-session&#8221;&gt;&lt;em&gt; Investor Sentiment Decreases Further, S&amp;P 500 Falls For Fourth Straight Session&lt;/em&gt;&lt;/a&gt;

Pre-Market Outlook

Markets

Movers

$USDT

ABAT

AILE

APTO

ATXS

BNRG

CNTM

EDBL

HSDT

JDZG

LAES

NSANY

ONFO

PHIO

RELI

SIGA

TPIC

Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket

Stifel analyst Steven Wieczynski maintains Carnival (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) with a Buy and raises the price target from $32 to $34.

Stifel Maintains Buy on Carnival, Raises Price Target to $34

CleanSpark Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>), America's Bitcoin Miner&#xAE; (the "Company"), today announced it has achieved and exceeded the previously announced year-end target of 37 EH/s of operating hashrate.
&nbsp;
The Company's newest data centers in Tennessee and Wyoming were energized last week. This is part of a multistage energization process that will continue into the next quarter. The added hashrate from these sites paired with site expansion, and ongoing fleet upgrades, has allowed the Company to exceed 2024 YE guidance and deliver 37.5 EH/s of operating hashrate. Fleet efficiency has reached 17.7 J/Th and is expected to continue to improve as the Company continues its strategic growth plans. The Company expects its operating leverage to continue to increase as it proceeds with its next phase of growth to 50 EH/s, which is fully funded and expected in the first half of 2025. This growth is expected to be achieved through a mix of greenfield infrastructure development, organic growth via existing site expansion, and strategic M&amp;A, all funded with a portion of the proceeds of the Company's most recent offering. The current portfolio of data centers includes locations in Georgia, Wyoming, Tennessee, Mississippi, and New York. &nbsp;&nbsp;

CLSK

CleanSpark Expands Data Centers, Surpasses 2024 Bitcoin Mining Target with 37.5 EH/s Hashrate, Aims for 50 EH/s in Early 2025

Truist Securities analyst Srikripa Devarakonda maintains Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) with a Buy and lowers the price target from $100 to $43.

KROS

Truist Securities Maintains Buy on Keros Therapeutics, Lowers Price Target to $43

The Company has received approval to begin enrollment of the Phase 1b clinical trial in Australia
Phase 1b clinical trial will assess safety and tolerability along with biomarkers during three months of dosing with GT-02287 in people diagnosed with Parkinson's disease
Phase 1b clinical trial follows successful Phase 1 study in which GT-02287 was safe and well tolerated while demonstrating GCase target engagement

GANX

Gain Therapeutics Initiated Phase 1b Clinical Trial Of Lead Candidate GT-02287 In People With GBA1 And Idiopathic Parkinson's Disease

Barclays analyst Carter Gould maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Overweight and raises the price target from $160 to $165.

NBIX

Barclays Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $165

NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) ("NewGen" or the "Company") today announced that both parties involved in the previously announced reverse merger with European Wellness Investment Holdings Limited ("EWIHL") have appointed legal counsel to prepare the Share Purchase Agreement (the "SPA"). Additionally, by mutual consent, the signing date for the SPA has been extended from January 27, 2025, to February 28, 2025. This extension will allow both parties sufficient time to complete the necessary due diligence, finalize the terms of the agreement, and ensure compliance with all relevant NASDAQ requirements for reverse mergers.
This significant step follows the Company's&nbsp;prior announcement of a binding term sheet on December 11, 2024, which marked a pivotal moment in the Company's strategic partnership with EWIHL. This collaboration aims to leverage synergies between both companies to enhance service delivery and expand market reach in the healthcare sector.

NIVF

NewGenIvf Extends Reverse Merger Deadline to Finalize Agreement with EWIHL

Raymond James analyst Buck Horne upgrades Weyerhaeuser (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) from Market Perform to Outperform and announces $32 price target.

Upgrades

Raymond James Upgrades Weyerhaeuser to Outperform, Announces $32 Price Target

QuickLogic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUIK#NASDAQ">QUIK</a>), a developer of embedded FPGA (eFPGA) Hard IP, ruggedized FPGAs, and endpoint AI solutions, announced today it has been awarded a $6.575 million contract. This funding will support the continued development and demonstration of Strategic Radiation Hardened (SRH) high reliability Field Programmable Gate Array (FPGA) technology. The initiative aims to meet current and future Department of Defense (DoD) strategic and space system requirements.

QUIK

QuickLogic Secures $6.6M Contract to Advance Radiation-Hardened FPGA Tech for DoD

RUM: 53% &#x7C; <a href="https://www.benzinga.com//node/42631159">Rumble shares are trading higher after the company announced it has entered into a definitive agreement for a strategic investment of $775 million from Tether.</a>
&nbsp;
TRAW: 212% &#x7C; <a href="https://www.benzinga.com//node/42643986">Traws Pharma Advances One-Dose Bird Flu Treatment with Results</a>
&nbsp;
RAPT: 94% &#x7C; <a href="https://www.benzinga.com//node/42644215">RAPT Therapeutics To Raise $150M in Private Placement to Advance Drug Pipeline</a>

RAPT

TRAW

Market-Moving News for December 23rd

Entertainment

Small Cap

Press Releases

General

RIVULET FILMS COMEDY 'NUTCRACKERS' STARRING BEN STILLER, TO RECEIVE OPENING NIGHT WORLD PREMIERE AT THE 49th ANNUAL TORONTO INTERNATIONAL FILM FESTIVAL

Comments

Rivulet Entertainment

Rivulet Entertainment (RIVF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga